Total raised
$1.3M
Last: Undisclosed 2021-11
Stage
Seed
Founded
2021
Headcount
4
HQ
Afula
Sector
Health Tech & Life Sciences
About
OphtiMed Rx is developing a novel molecular therapy for dry age-related macular degeneration (AMD), a common eye disease leading to blindness. The company’s treatment protects retinal cells from senescence (cellular aging) and can halt the progression of dry AMD.
OphtiMed Rx’s therapy is designed to prevent the loss of vision and independence caused by dry AMD, providing an enormous benefit to patients.
Funding history · 1 round · $1.3M total
2021-11
Undisclosed
$1.3M
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesHealthcareLaboratories
Business model
B2B
Highlights
1 PatentsVerified
Tags
pharmaceuticalspharma-companiesdrug-discoveryprivate-investorsophthalmologyinvestorseye-diseasesdrug-development